Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Clinical trial NCT01274351 · COMPLETED
Trial details
- NCT number
- NCT01274351
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-01-25
- Primary completion
- 2019-08-01
- Enrollment
- 112
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.